A 16-Week Study to Learn About Ritlecitinib for Hidradenitis Suppurativa
Phase 2
240
about 1.4 years
18–75
4 sites in CA, IN, MI +1
About this study
This trial is testing a treatment called Ritlecitinib in adults with hidradenitis suppurativa (HS), a condition causing painful red skin lumps. Participants will be randomly assigned to receive either Ritlecitinib or a placebo pill, taking it daily at home for about 24 weeks. It involves regular clinic visits and symptom tracking via an eDiary.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take Ritlecitinib
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
ritlecitinib
oral (Oral Capsule)
Secondary: Absolute score and CFB in Hidradenitis Suppurativa Quality of Life (HiSQOL), CFB in Hidradenitis Suppurativa Symptom Daily Diary (HSSDD), CFB in skin pain NRS, at worst and on average, respectively, Incidence of treatment emergent adverse events (TEAE), adverse events (AE) and serious adverse events (SAE) leading to discontinuation, Percent CFB in skin pain NRS, at worst and on average, respectively, in participants with baseline skin pain NRS ≥3, Percent change from Baseline(CFB) in total AN count, Skin pain NRS30 (numeric rating scale) response, at worst and on average, respectively among participants with baseline skin pain NRS ≥3, Skin pain NRS50 response, at worst and on average, respectively among participants with baseline skin pain NRS ≥3.